BlackRock Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

BlackRock Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$9K	Hold	13	–	–	﹤0.01%	3582
2016 Q3	$14K	Hold	13	–	–	﹤0.01%	3526
2016 Q2	$10K	Hold	13	–	–	﹤0.01%	3579
2016 Q1	$9K	Hold	13	–	–	﹤0.01%	3592
2015 Q4	$12K	Hold	13	–	–	﹤0.01%	3605
2015 Q3	$14K	Hold	13	–	–	﹤0.01%	3596
2015 Q2	$26K	Hold	13	–	–	﹤0.01%	3445
2015 Q1	$12K	Hold	13	–	–	﹤0.01%	3521
2014 Q4	$13K	Sell	13 -68	-84%	-$60.7K	﹤0.01%	3582
2014 Q3	$84K	Hold	81	–	–	﹤0.01%	3097
2014 Q2	$156K	Sell	81 -6	-7%	-$11.9K	﹤0.01%	2795
2014 Q1	$187K	Buy	87 +69	+383%	+$172K	﹤0.01%	2677
2013 Q4	$41K	Sell	18 -20	-53%	-$45.7K	﹤0.01%	3279
2013 Q3	$109K	Buy	38 +26	+217%	+$129K	﹤0.01%	2910
2013 Q2	$109K	Buy	+12	New	+$92.5K	﹤0.01%	2847

Other funds holding ONCT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FHA

First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DAM

Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return

KLI

Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BlackRock Advisors's ONCT Position: Q4 2016 in Review

BlackRock Advisors held its Oncternal Therapeutics, Inc. Common Stock (ONCT) position steady in Q4 2016 at 13 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #3582.

BlackRock Advisors first reported a position in ONCT in Q2 2013 and has held it in 15 quarters since. The position peaked at $187K in Q1 2014. 21 funds tracked by Wall St. Rank hold ONCT as of Q4 2016.

BlackRock Advisors held 13 shares of Oncternal Therapeutics, Inc. Common Stock worth $9K as of Q4 2016.
BlackRock Advisors left its Oncternal Therapeutics, Inc. Common Stock share count unchanged in Q4 2016.
Oncternal Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3582 holding.
BlackRock Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $187K in Q1 2014.
21 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.